GSK’s experimental HIV drug trial produces positive results

GSK’s experimental HIV drug trial produces positive results

U.K.-based GlaxoSmithKline PLC’s ViiV Healthcare on Tuesday announced positive results for its phase-three trial of its experimental HIV drug in a dual-drug regimen.

The company announced that the combination of its HIV pill dolutegravir and Johnson & Johnson’s (J&J’s) rilpivirine drug successfully suppressed the HIV virus as capably as the existing three- or four-drug regimen can.

The positive results of the year-long trial, involving nearly 500 patients, supported Glaxo’s bold bet that it can shift the HIV treatment orthodoxy away from three-drug combinations to two-drug regimen.

The results of the trial also raised the possibility of a challenge to incumbent companies like Gilead.

UBS analyst Michael Leuchten said, “The key debate remains whether Gilead will gain the upper hand again or whether a disruptive two-drug regimen becomes standard of care, favoring GSK.”

Reducing the number of drugs will lower antiretroviral medicine’s side effects, such as nausea, diarrhea, bone-thinning and kidney problems. In addition, it will lighten the patient’s financial burden.

Dominique Limet, the chief of ViiV Healthcare, said the two-drug regimen would be submitted to regulators sometime next year. However, both medicines used in the two-drug regimen are already sold as components in combinations of three or more drugs.


Popular Stories

Facebook preparing to demote slow-loading stories on News Feed

Facebook, the world’s largest social network, is... Read More

Facebook reportedly working on dedicated video chat device

Social-networking giant Facebook is reportedly... Read More

Mario Draghi was right in keeping inflation expectations low

The European Central Bank’s president, Mario Draghi... Read More

Sprint reportedly proposes merger with Charter

Seeking an alternative to a deal with T-Mobile USA... Read More

Barclays results depict bleak picture of South African economy

Johannesburg-based Barclays Africa Group’s... Read More

Barclays Africa reports decline in first-half income

Barclays Africa Group Limited on Thursday reported... Read More